Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.

被引：6
|
作者：
Smyth, Elizabeth Catherine
Turner, Nicholas C.
Pearson, Alex
Peckitt, Clare
Chau, Ian
Watkins, David J.
Starling, Naureen
Rao, Sheela
Gillbanks, Angela
Kilgour, Elaine
Sumpter, Katherine Anne
Smith, Neil R.
Cutts, Ros
Rooney, Claire
Thomas, Anne L.
Ajaz, Mazhar A.
Chua, Sue
Brown, Gina
Popat, Sanjay
Cunningham, David
机构：
[1] Royal Marsden, London, England
[2] Inst Canc Res, London SW3 6JB, England
[3] Royal Marsden Hosp, London SW3 6JJ, England
[4] AstraZeneca Oncol Innovat Med, Macclesfield, Cheshire, England
[5] Northern Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[6] Leicester Royal Infirm, Leicester, Leics, England
[7] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.154
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
154
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Biomarker driven phase II umbrella trial study of AZD1775,AZD2014,AZD2811 monotherapy in relapsed small cell lung cancer.
    Park, Sehhoon
    Shim, Joonho
    Jung, Hyun Ae
    Sun, Jong-Mu
    Lee, Se-Hoon
    Park, Woong-Yang
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.
    Takahashi, Shunji
    Kiyota, Naomi
    Yamazaki, Tomoko
    Chayahara, Naoko
    Nakano, Kenji
    Inagaki, Lina
    Toda, Kazuhisa
    Enokida, Tomohiro
    Minami, Hironobu
    Imamura, Yoshinori
    Sasaki, Tatsuya
    Suzuki, Takuya
    Fujino, Katsuki
    Dutcus, Corina
    Tahara, Makoto
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Early clinical evaluation of FGFR1 inhibition in lung cancer: Preliminary results of a phase I study in FGFR1 amplified lung cancer patients treated with BGJ398, a pan FGFR inhibitor
    Nogova, L.
    Gardizi, M.
    Bos, M. C. A.
    Bitter, E.
    Schildhaus, H. -U
    Heukamp, L. C.
    Toepelt, K.
    Zander, T.
    Scheffler, M.
    Mattonet, C.
    Goekkurt, E.
    Risse, F.
    Schuler, M.
    Sequist, L.
    Tian, G. G.
    Ringeisen, F.
    Thomas, R.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2012, 35 : 137 - 137
  • [34] Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.
    Riess, Hanno
    Van Laethem, Jean-Luc
    Martens, Uwe Marc
    Heinemann, Volker
    Michl, Patrick
    Peeters, Marc
    Van Brummelen, David
    Weekes, Colin D.
    Dueland, Svein
    Schmiegel, Wolff H.
    Giurescu, Marius
    Garosi, Vittorio Luigi
    Schulz, Anke
    Seidel, Henrik
    Childs, Barrett H.
    Teufel, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] A Population-Based Cohort Study on Chronic Obstructive Pulmonary Disease in Latin America: Methods and Preliminary Results. The PLATINO Study Phase II
    Menezes, Ana Maria Baptista
    Muino, Adriana
    Lopez-Varela, Maria Victorina
    Valdivia, Gonzalo
    Lisboa, Carmen
    Jardime, Jose Roberto
    de Oca, Maria Montes
    Talamo, Carlos
    Wehrmeister, Fernando Cesar
    Perez-Padilla, Rogelio
    Platinoo, Equipo del Estudio
    ARCHIVOS DE BRONCONEUMOLOGIA, 2014, 50 (01): : 10 - 17
  • [36] Cabozantinib (cabo) combined with durvalumab (durva) in gastroesophageal (GE) cancer and other gastrointestinal (GI) malignancies: Preliminary phase Ib CAMILLA study results.
    Saeed, Anwaar
    Phadnis, Milind
    Park, Robin
    Sun, Weijing
    Al-Rajabi, Raed Moh'd Taiseer
    Baranda, Joaquina Celebre
    Williamson, Stephen K.
    Collins, Zachary
    Firth-Braun, Jeanette
    Saeed, Azhar
    Foster, Carolyn
    Roberts, Benjamin
    Subramaniam, Dharmalingam
    Kasi, Anup
    Anant, Shrikant
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Phase II study of gemcitabine (G) and doxil (D) combination chemotherapy in patients with metastatic breast cancer: preliminary results.
    Rivera, E
    Arun, B
    Royce, M
    Adinin, R
    Valero, V
    Hoelzer, K
    Walters, R
    Wade, J
    Pusztai, L
    Hortobagyi, GN
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S92 - S92
  • [38] Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results.
    Makarova-Rusher, Oxana V.
    Duffy, Austin G.
    Ulahannan, Susanna Varkey
    Fioravanti, Suzanne
    Walker, Melissa
    Raffeld, Mark
    Compton, Kathryn
    Lee, Sunmin
    Tomita, Yusuke
    Trepel, Jane B.
    Figg, William Douglas
    Greten, Tim F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [39] PETRANHA: Phase 1/2 study of AZD5305+novel hormonal agents in patients with metastatic prostate cancer-Interim safety and pharmacokinetic results.
    Azad, Arun
    Voskoboynik, Mark
    Joshua, Anthony M.
    Weickhardt, Andrew James
    Sankey, Peter
    Pacey, Simon
    Heath, Elisabeth I.
    Krieger, Laurence
    Horvath, Lisa
    Pilie, Patrick Glen
    Womersley, Lynsey
    Linardopoulos, Spiros
    Moorthy, Ganesh
    Zhou, T. J.
    Brown, Jessica
    de Paula, Bruno
    Lukacs, Edit
    Hudson, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 123 - 123
  • [40] FINESSE - An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified oestrogeN rEceptor poSitive metaStatic breast cancEr
    Andre, F.
    Daly, F.
    Azim, H. A., Jr.
    Agrapart, V.
    Fumagalli, D.
    Gingras, I.
    Guitart, M.
    Lange, A.
    Turner, N. C.
    Pierrat, M-J
    Loibl, S.
    Poirot, C.
    Curigliano, G.
    Loi, S.
    Pallis, A.
    Piccart, M.
    Cortes, J.
    CANCER RESEARCH, 2016, 76
12345